The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

BACKGROUND: The 21-gene Recurrence Score (RS) result predicts outcome and chemotherapy benefit in node-negative and node-positive (N+), estrogen receptor-positive (ER+) patients treated with endocrine therapy. The purpose of this study was to evaluate the prognostic impact of RS results in N+, hormo...

Descripción completa

Detalles Bibliográficos
Autores principales: Penault-Llorca, Frédérique, Filleron, Thomas, Asselain, Bernard, Baehner, Frederick L., Fumoleau, Pierre, Lacroix-Triki, Magali, Anderson, Joseph M., Yoshizawa, Carl, Cherbavaz, Diana B., Shak, Steven, Roca, Lise, Sagan, Christine, Lemonnier, Jérôme, Martin, Anne-Laure, Roché, Henri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936023/
https://www.ncbi.nlm.nih.gov/pubmed/29728098
http://dx.doi.org/10.1186/s12885-018-4331-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936023/
https://www.ncbi.nlm.nih.gov/pubmed/29728098
http://dx.doi.org/10.1186/s12885-018-4331-8

Ejemplares similares